Abstract
Background and Objectives: Janumet® XR is a fixed-dose combination of sitagliptin and extended-release metformin hydrochloride. While effective, its high cost limits accessibility. This study compared the bioequivalence (BE) of a generic version produced by Nanjing Chia-Tai Tianqing Pharmaceutical Company to the branded Janumet® XR in healthy Chinese subjects.
Methods: Two separate studies (fasting and fed) were conducted using an open, randomized, two-period crossover design with 28 subjects each. Plasma concentrations were measured up to 72 h post-dose to calculate $C_{max}$ and $AUC$.
Results: In both fasting and fed states, the 90% CIs for $C_{max}$, $AUC_{0-t}$, and $AUC_{0-\infty}$ for both sitagliptin and metformin were within the 80.00%–125.00% acceptance limits.
Conclusion: The generic formulation is bioequivalent to Janumet® XR and was well tolerated, offering a potentially more affordable treatment option for diabetes.
Introduction
Managing Type 2 Diabetes Mellitus (T2DM) often requires a multi-drug regimen to achieve glycemic control. JANUMET® XR simplifies treatment by combining sitagliptin (a DPP-4 inhibitor) and metformin (a biguanide) into a single, once-daily extended-release tablet. Despite its clinical benefits, the high cost of brand-name medications often leads to reduced patient adherence. To introduce a more affordable generic version, manufacturers must demonstrate bioequivalence (BE), ensuring the generic "Test" drug performs identically to the "Reference" drug in the human body.
Methods
The researchers conducted two separate studies (fasting and fed) using an open-label, randomized, two-period crossover design. 56 healthy Chinese volunteers (28 per study) were enrolled based on specific inclusion criteria, including age 18+ and a BMI between 19–26 $kg/m^2$.
As shown in the study design (Figure 1), subjects were randomized to receive either the Test (T) or Reference (R) drug on Day 1, followed by a 7-day washout period before crossing over to the alternate treatment on Day 8. Blood samples were collected at 19 time points over 72 hours. Plasma concentrations were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Bioequivalence was confirmed if the 90% Confidence Interval (CI) of the T/R ratio for $C_{max}$ and $AUC$ fell between 80.00% and 125.00%.
Results
The generic drug successfully met all regulatory bioequivalence criteria in both physiological states:
- Fasting Study: Geometric mean ratios (T/R) for sitagliptin $C_{max}$ and $AUC_{0-t}$ were 109.42% and 101.93%, respectively. For metformin, they were 98.69% and 94.12%.
- Fed Study: Ratios for sitagliptin $C_{max}$ and $AUC_{0-t}$ were 98.41% and 100.30%. For metformin, they were 97.79% and 99.28%.
All 90% CIs for these parameters were strictly within the 80.00%–125.00% range. Both treatments were well-tolerated, with only mild, expected adverse events such as transient hypoglycemia in fasting subjects, which was managed with standard safety protocols including 20% glucose solutions.
Discussion
The study highlights the technical success of mimicking the complex formulation of JANUMET® XR, which features an extended-release metformin core with a sitagliptin coating. Furthermore, it demonstrated that while food intake alters the absolute pharmacokinetics of these drugs—increasing sitagliptin $C_{max}$ while decreasing metformin $C_{max}$—the generic and brand-name formulations remain bioequivalent relative to each other under both conditions.
Conclusion
This study provides the first demonstration that the generic sitagliptin/metformin HCl extended-release tablets produced by Nanjing Chia-Tai Tianqing Pharmaceutical Company are bioequivalent to the branded JANUMET® XR. These findings support the use of this generic formulation as a safe, effective, and more affordable alternative for the management of Type 2 Diabetes.
Summary updated